​

BioMarin Pharmaceutical (BMRN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BMRN Stock Forecast

BioMarin Pharmaceutical stock forecast is as follows: an average price target of $94.43 (represents a 43.82% upside from BMRN’s last price of $65.66) and a rating consensus of 'Buy', based on 17 wall street analysts offering a 1-year stock forecast.

BMRN Price Target

The average price target for BioMarin Pharmaceutical (BMRN) is $94.43 based on 1-year price targets from 17 Wall Street analysts in the past 3 months, with a price target range of $115.00 to $65.00. This represents a potential 43.82% upside from BMRN's last price of $65.66.

BMRN Analyst Ratings

Buy

According to 17 Wall Street analysts, BioMarin Pharmaceutical's rating consensus is 'Buy'. The analyst rating breakdown for BMRN stock is 0 'Strong Buy' (0.00%), 11 'Buy' (64.71%), 6 'Hold' (35.29%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

BioMarin Pharmaceutical Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 30, 2024Olivia BrayerCantor Fitzgerald$90.00$67.0034.33%37.07%
Oct 30, 2024Jack AllenRobert W. Baird$65.00$69.91-7.02%-1.01%
Oct 30, 2024David LebowitzCitigroup$81.00$69.9115.86%23.36%
Oct 10, 2024Danielle BrillRaymond James$79.00$69.5913.51%20.32%
Oct 04, 2024Gena WangBarclays$86.00$69.5123.72%30.98%
Sep 18, 2024David LebowitzCitigroup$93.00$71.1430.73%41.64%
Sep 17, 2024George FarmerScotiabank$78.00$71.219.54%18.79%
Sep 17, 2024Joon LeeTruist Financial$90.00$71.2026.40%37.07%
Sep 17, 2024William PickeringBernstein$90.00$69.8628.83%37.07%
Sep 17, 2024Kostas BiliourisBMO Capital$115.00$71.1361.68%75.14%
Sep 16, 2024Gena WangBarclays$110.00$69.8657.46%67.53%
Sep 05, 2024Christopher RaymondRaymond James$122.00$86.7440.65%85.81%
Sep 05, 2024George FarmerScotiabank$95.00$86.759.51%44.68%
Aug 27, 2024Christopher RaymondRaymond James$107.00$88.6920.64%62.96%
Aug 21, 2024Paul MatteisStifel Nicolaus$115.00$93.8422.55%75.14%
Aug 20, 2024William PickeringTudor Pickering$110.00$94.2016.77%67.53%
Aug 06, 2024Cory KasimovEvercore ISI$115.00$85.9833.74%75.14%
Aug 06, 2024Paul MatteisStifel Nicolaus$112.00$85.9830.26%70.58%
Aug 06, 2024Whitney IjemCanaccord Genuity$93.00$80.4715.57%41.64%
Jun 27, 2024Mohit BansalWells Fargo$115.00$85.2534.90%75.14%
Jun 04, 2024William PickeringTudor Pickering$91.00$78.8715.38%38.59%
May 17, 2024Jack AllenRobert W. Baird$72.00$76.97-6.46%9.66%
May 13, 2024Cory KasimovEvercore ISI$113.00$80.5040.37%72.10%
Apr 25, 2024George FarmerScotiabank$85.00$91.20-6.80%29.45%
Apr 22, 2024Eliana MerleUBS$119.00$89.4932.98%81.24%
Jul 05, 2023Kostas BiliourisBMO Capital$102.00$85.8918.76%55.35%
Oct 26, 2022Christopher RaymondRaymond James$128.00$92.1038.98%94.94%
Sep 12, 2022Robyn KarnauskasTruist Financial$133.00$89.4148.75%102.56%
Jul 12, 2022Olivia BrayerCantor Fitzgerald$110.00$87.8525.21%67.53%
Apr 25, 2022Matthew HarrisonMorgan Stanley$113.00$80.5040.37%72.10%
Feb 22, 2022Joshua SchimmerEvercore ISI$105.00$85.3722.99%59.91%
Feb 18, 2022Matthew HarrisonMorgan Stanley$90.00$84.866.06%37.07%
Jan 10, 2022Geoff MeachamBank of America Securities$120.00$84.3942.20%82.76%
Dec 08, 2021Phil NadeauCowen & Co.$135.00$88.3852.75%105.60%
Nov 22, 2021Tiago FauthCredit Suisse$105.00$90.3016.28%59.91%
Nov 19, 2021Debjit ChattopadhyayGuggenheim$120.00$91.4731.19%82.76%

The latest BioMarin Pharmaceutical stock forecast, released on Oct 30, 2024 by Olivia Brayer from Cantor Fitzgerald, set a price target of $90.00, which represents a 34.33% increase from the stock price at the time of the forecast ($67.00), and a 37.07% increase from BMRN last price ($65.66).

BioMarin Pharmaceutical Price Target by Period

1M3M12M
# Anlaysts-625
Avg Price Target-$82.33$97.64
Last Closing Price$65.66$65.66$65.66
Upside/Downside-100.00%25.39%48.71%

In the current month, the average price target of BioMarin Pharmaceutical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to BioMarin Pharmaceutical's last price of $65.66. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 04, 2024WedbushNeutralOutperformUpgrade
Oct 30, 2024RBC CapitalSector PerformSector PerformHold
Oct 30, 2024Evercore ISIOutperformOutperformHold
Oct 30, 2024William BlairSector PerformSector PerformHold
Oct 30, 2024Cantor FitzgeraldOverweightOverweightHold
Oct 30, 2024CitigroupNeutralNeutralHold
Oct 30, 2024William BlairSector PerformMarket PerformDowngrade
Oct 04, 2024William BlairSector PerformSector PerformHold
Oct 04, 2024Wells FargoUnderperformUnderperformHold
Sep 18, 2024CitigroupNeutralNeutralHold
Sep 17, 2024BernsteinOutperformOutperformHold
Sep 17, 2024BMO CapitalOutperformOutperformHold
Sep 16, 2024BarclaysOverweightOverweightHold
Sep 13, 2024Canaccord GenuityHoldHoldHold
Sep 05, 2024Stifel NicolausUnderperformUnderperformHold
Sep 05, 2024Cowen & Co.BuyBuyHold
Sep 05, 2024ScotiabankSector PerformSector PerformHold
Sep 04, 2024Cantor FitzgeraldOverweightOverweightHold
Aug 27, 2024Piper SandlerOverweightOverweightHold
Aug 20, 2024ScotiabankUnderperformUnderperformHold
Aug 20, 2024Wells FargoSector PerformSector PerformHold
Aug 20, 2024BernsteinMarket PerformOutperformUpgrade
Aug 06, 2024William BlairOutperformOutperformHold
Aug 06, 2024Cowen & Co.BuyBuyHold
Aug 06, 2024ScotiabankSector PerformSector PerformHold
Aug 06, 2024Evercore ISIOutperformOutperformHold
Jul 22, 2024ScotiabankUnderperformUnderperformHold
Jul 22, 2024Wells FargoSector PerformSector PerformHold
Jun 27, 2024Wells FargoSector PerformSector PerformHold
Jun 27, 2024ScotiabankUnderperformUnderperformHold
Jun 27, 2024Wells FargoOverweightOverweightHold
Jun 07, 2024CitigroupNeutralNeutralHold
Jun 04, 2024BernsteinMarket PerformMarket PerformHold
Jun 04, 2024Wells FargoOverweightOverweightHold
May 14, 2024Wells FargoSector PerformSector PerformHold
May 14, 2024ScotiabankUnderperformUnderperformHold
May 13, 2024Evercore ISIOutperformInitialise
May 06, 2024CitigroupNeutralNeutralHold
Apr 25, 2024Wells FargoOverweightOverweightHold
Apr 25, 2024ScotiabankSector PerformSector PerformHold
Apr 22, 2024UBSBuyBuyHold
Feb 23, 2024RBC CapitalSector PerformSector PerformHold
Feb 23, 2024Cantor FitzgeraldUnderperformUnderperformHold
Jan 30, 2024RBC CapitalSector PerformSector PerformHold
Jan 30, 2024Piper SandlerUnderperformUnderperformHold
Dec 21, 2023RBC CapitalSector PerformSector PerformHold
Oct 23, 2023BernsteinMarket PerformUpgrade
Sep 28, 2023Raymond JamesMarket PerformInitialise
Jul 05, 2023BMO CapitalPerformOutperformUpgrade
Jun 30, 2023BMO CapitalPerformPerformHold
Jun 30, 2023WedbushNeutralNeutralHold
Oct 31, 2022OppenheimerOutperformUpgrade
Oct 26, 2022Piper SandlerOverweightOverweightHold
Apr 25, 2022Morgan StanleyOverweightUpgrade
Feb 24, 2022Piper SandlerOverweightOverweightHold

BioMarin Pharmaceutical's last stock rating was published by Wedbush on Nov 04, 2024. The company Upgrade its BMRN rating from "Neutral" to "Outperform".

BioMarin Pharmaceutical Financial Forecast

BioMarin Pharmaceutical Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$646.21B$581.33B$595.27M$596.41M$537.54M$505.34M$533.80M$519.36M$449.81M$408.74M$501.69M$486.07M$452.12M$476.78M$429.49M$502.07M$454.44M$461.10M
Avg Forecast$846.96M$863.59M$840.29M$832.33M$788.97M$772.82M$754.22M$725.81M$711.42M$703.43M$663.98M$651.83M$638.82M$603.84M$595.23M$570.35M$537.62M$518.45M$520.20M$510.95M$442.38M$435.30M$448.31M$446.35M$439.33M$457.38M$418.62M$468.58M$457.91M$455.76M
High Forecast$889.48M$906.93M$882.47M$874.11M$828.57M$811.61M$792.07M$767.00M$729.17M$703.94M$665.25M$652.09M$663.25M$660.00M$625.11M$598.98M$564.60M$518.45M$520.20M$510.95M$442.38M$435.30M$448.31M$446.35M$439.33M$457.38M$418.62M$468.58M$457.91M$455.76M
Low Forecast$785.77M$801.19M$779.58M$772.20M$731.97M$716.98M$699.72M$668.89M$685.49M$702.92M$662.71M$651.56M$625.52M$573.53M$552.23M$529.15M$498.78M$518.45M$520.20M$510.95M$442.38M$435.30M$448.31M$446.35M$439.33M$457.38M$418.62M$468.58M$457.91M$455.76M
# Analysts10755854111996612191898811151799101177986
Surprise %------------1011.57%962.72%1.00%1.05%1.00%0.97%1.03%1.02%1.02%0.94%1.12%1.09%1.03%1.04%1.03%1.07%0.99%1.01%

BioMarin Pharmaceutical's average Quarter revenue forecast for Mar 24 based on 6 analysts is $651.83M, with a low forecast of $651.56M, and a high forecast of $652.09M. BMRN's average Quarter revenue forecast represents a -99.90% decrease compared to the company's last Quarter revenue of $646.21B (Dec 23).

BioMarin Pharmaceutical EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts10755854111996612191898811151799101177986
EBITDA------------$14.22B$25.66B$99.98M$86.88M$10.62M$27.58M$63.98M$57.34M$-37.34M$-15.45M$45.06M$55.02M$-8.08M$-24.98M$-9.53M$134.23M$22.43M$42.99M
Avg Forecast$50.59M$51.59M$50.20M$49.72M$47.13M$46.16M$45.05M$43.36M$42.50M$42.02M$39.66M$261.07M$38.16M$36.07M$35.56M$237.34M$-41.07M$20.14M$20.21M$253.84M$17.18M$16.91M$17.41M$162.69M$17.06M$17.77M$16.26M$18.20M$17.79M$17.70M
High Forecast$53.13M$54.18M$52.71M$52.22M$49.50M$48.48M$47.31M$45.82M$43.56M$42.05M$39.74M$313.29M$39.62M$39.43M$37.34M$284.81M$-32.85M$20.14M$20.21M$304.61M$17.18M$16.91M$17.41M$195.22M$17.06M$17.77M$16.26M$18.20M$17.79M$17.70M
Low Forecast$46.94M$47.86M$46.57M$46.13M$43.72M$42.83M$41.80M$39.96M$40.95M$41.99M$39.59M$208.86M$37.37M$34.26M$32.99M$189.87M$-49.28M$20.14M$20.21M$203.07M$17.18M$16.91M$17.41M$130.15M$17.06M$17.77M$16.26M$18.20M$17.79M$17.70M
Surprise %------------372.61%711.41%2.81%0.37%-0.26%1.37%3.17%0.23%-2.17%-0.91%2.59%0.34%-0.47%-1.41%-0.59%7.38%1.26%2.43%

6 analysts predict BMRN's average Quarter EBITDA for Mar 24 to be $261.07M, with a high of $313.29M and a low of $208.86M. This is -98.16% lower than BioMarin Pharmaceutical's previous annual EBITDA (Dec 23) of $14.22B.

BioMarin Pharmaceutical Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts10755854111996612191898811151799101177986
Net Income------------$20.38B$40.38B$56.04M$50.85M$-249.00K$-6.65M$27.66M$120.80M$-57.90M$-36.49M$12.94M$17.37M$22.10M$784.80M$-29.18M$81.38M$15.02M$55.04M
Avg Forecast$46.59M$52.62M$56.29M$62.16M$149.57M$152.67M$141.39M$124.98M$107.63M$104.68M$70.54M$190.75M$38.87M$43.28M$41.67M$173.41M$-63.69M$-2.41M$6.60M$185.46M$-72.68M$-50.14M$-21.89M$51.37M$-33.71M$50.13M$-22.58M$498.05M$-7.32M$11.82M
High Forecast$49.63M$56.05M$59.96M$66.22M$159.32M$162.63M$150.61M$152.42M$118.10M$105.56M$70.56M$228.90M$51.24M$72.79M$44.39M$208.09M$-50.95M$-2.41M$6.60M$222.55M$-72.68M$-50.14M$-21.89M$61.64M$-33.71M$50.13M$-22.58M$597.66M$-7.32M$11.82M
Low Forecast$42.21M$47.68M$51.00M$56.32M$135.52M$138.33M$128.11M$94.50M$94.18M$103.79M$70.53M$152.60M$34.45M$23.61M$37.76M$138.72M$-76.43M$-2.41M$6.60M$148.37M$-72.68M$-50.14M$-21.89M$41.09M$-33.71M$50.13M$-22.58M$398.44M$-7.32M$11.82M
Surprise %------------524.19%932.91%1.34%0.29%0.00%2.76%4.19%0.65%0.80%0.73%-0.59%0.34%-0.66%15.66%1.29%0.16%-2.05%4.66%

BioMarin Pharmaceutical's average Quarter net income forecast for Mar 24 is $190.75M, with a range of $152.60M to $228.90M. BMRN's average Quarter net income forecast represents a -99.06% decrease compared to the company's last Quarter net income of $20.38B (Dec 23).

BioMarin Pharmaceutical SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts10755854111996612191898811151799101177986
SG&A------------$275.02B$223.93B$215.34M$223.00M$245.74M$216.82M$196.84M$194.62M$217.60M$183.30M$184.20M$174.30M$195.54M$179.45M$175.40M$202.97M$204.89M$187.18M
Avg Forecast$339.17M$345.83M$336.50M$333.31M$315.95M$309.48M$302.03M$290.65M$284.89M$281.69M$265.89M$307.31M$255.82M$241.81M$238.36M$279.38M$239.36M$207.64M$208.34M$298.80M$177.17M$174.34M$179.55M$178.76M$175.95M$183.18M$167.65M$187.66M$183.39M$182.53M
High Forecast$356.19M$363.18M$353.39M$350.04M$331.81M$325.01M$317.19M$307.15M$292.00M$281.90M$266.40M$368.78M$265.60M$264.30M$250.33M$335.25M$287.23M$207.64M$208.34M$358.56M$177.17M$174.34M$179.55M$178.76M$175.95M$183.18M$167.65M$187.66M$183.39M$182.53M
Low Forecast$314.67M$320.84M$312.19M$309.23M$293.12M$287.12M$280.21M$267.86M$274.51M$281.49M$265.38M$245.85M$250.49M$229.67M$221.14M$223.50M$191.49M$207.64M$208.34M$239.04M$177.17M$174.34M$179.55M$178.76M$175.95M$183.18M$167.65M$187.66M$183.39M$182.53M
Surprise %------------1075.08%926.05%0.90%0.80%1.03%1.04%0.94%0.65%1.23%1.05%1.03%0.98%1.11%0.98%1.05%1.08%1.12%1.03%

BioMarin Pharmaceutical's average Quarter SG&A projection for Mar 24 is $307.31M, based on 6 Wall Street analysts, with a range of $245.85M to $368.78M. The forecast indicates a -99.89% fall compared to BMRN last annual SG&A of $275.02B (Dec 23).

BioMarin Pharmaceutical EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts10755854111996612191898811151799101177986
EPS------------$0.11$214.53$0.30$0.27$-0.00$-0.04$0.15$0.66$-0.32$-0.20$0.07$0.10$0.12$4.33$-0.16$0.45$0.08$0.31
Avg Forecast$0.24$0.27$0.29$0.32$0.76$0.77$0.72$0.63$0.55$0.53$0.36$0.31$0.20$0.22$0.21$0.16$-0.06$-0.01$0.03$0.21$-0.36$-0.25$-0.11$-0.09$-0.17$0.25$-0.11$0.03$-0.04$0.06
High Forecast$0.25$0.28$0.30$0.34$0.81$0.82$0.76$0.77$0.60$0.54$0.36$0.32$0.26$0.37$0.23$0.17$-0.05$-0.01$0.03$0.21$-0.36$-0.25$-0.11$-0.09$-0.17$0.25$-0.11$0.03$-0.04$0.06
Low Forecast$0.21$0.24$0.26$0.29$0.69$0.70$0.65$0.48$0.48$0.53$0.36$0.31$0.17$0.12$0.19$0.14$-0.06$-0.01$0.03$0.21$-0.36$-0.25$-0.11$-0.09$-0.17$0.25$-0.11$0.03$-0.04$0.06
Surprise %------------0.56%977.18%1.42%1.74%0.02%2.98%4.56%3.11%0.88%0.80%-0.64%-1.12%-0.71%17.32%1.42%14.49%-2.19%5.26%

According to 6 Wall Street analysts, BioMarin Pharmaceutical's projected average Quarter EPS for Mar 24 is $0.31, with a low estimate of $0.31 and a high estimate of $0.32. This represents a 183.48% increase compared to BMRN previous annual EPS of $0.11 (Dec 23).

BioMarin Pharmaceutical Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
LEGNLegend Biotech$34.68$89.60158.36%Buy
MREOMereo BioPharma Group$3.40$8.00135.29%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
LQDALiquidia$11.31$22.3397.44%Buy
AMLXAmylyx Pharmaceuticals$4.28$8.2592.76%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
PCVXVaxcyte$89.86$148.8065.59%Buy
IONSIonis Pharmaceuticals$37.68$58.3354.80%Buy
BMRNBioMarin Pharmaceutical$67.19$94.4340.54%Buy
INCYIncyte$69.40$90.1129.84%Buy
AGIOAgios Pharmaceuticals$41.96$53.5027.50%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
ALNYAlnylam Pharmaceuticals$246.58$310.6025.96%Buy
ARWRArrowhead Pharmaceuticals$22.27$27.7424.56%Buy
TECHBio-Techne$75.27$82.339.38%Buy
HALOHalozyme Therapeutics$48.60$52.007.00%Buy
EXELExelixis$34.69$30.89-10.95%Buy

BMRN Forecast FAQ

Is BioMarin Pharmaceutical a good buy?

Yes, according to 17 Wall Street analysts, BioMarin Pharmaceutical (BMRN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 64.71% of BMRN's total ratings.

What is BMRN's price target?

BioMarin Pharmaceutical (BMRN) average price target is $94.43 with a range of $65 to $115, implying a 43.82% from its last price of $65.66. The data is based on 17 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will BioMarin Pharmaceutical stock go up soon?

According to Wall Street analysts' prediction for BMRN stock, the company can go up by 43.82% (from the last price of $65.66 to the average price target of $94.43), up by 75.14% based on the highest stock price target, and down by -1.01% based on the lowest stock price target.

Can BioMarin Pharmaceutical stock reach $100?

BMRN's highest twelve months analyst stock price target of $115 supports the claim that BioMarin Pharmaceutical can reach $100 in the near future.

What are BioMarin Pharmaceutical's analysts' financial forecasts?

BioMarin Pharmaceutical's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.04B (high $3.2B, low $2.82B), average EBITDA is $181.7M (high $191.11M, low $168.31M), average net income is $568.61M (high $624.99M, low $496.46M), average SG&A $1.22B (high $1.28B, low $1.13B), and average EPS is $2.88 (high $3.17, low $2.52). BMRN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $3.38B (high $3.55B, low $3.14B), average EBITDA is $202.1M (high $212.24M, low $187.49M), average net income is $217.65M (high $231.85M, low $197.21M), average SG&A $1.35B (high $1.42B, low $1.26B), and average EPS is $1.1 (high $1.18, low $1).

Did the BMRN's actual financial results beat the analysts' financial forecasts?

Based on BioMarin Pharmaceutical's last annual report (Dec 2023), the company's revenue was $2.42T, beating the average analysts forecast of $2.41B by 100355.98%. Apple's EBITDA was $158.1B, beating the average prediction of $347.13M by 45444.44%. The company's net income was $167.64B, beating the average estimation of $297.23M by 56302.52%. Apple's SG&A was $937.29B, beating the average forecast of $1.02B by 92210.65%. Lastly, the company's EPS was $0.87, beating the average prediction of $0.783 by 11.09%. In terms of the last quarterly report (Dec 2023), BioMarin Pharmaceutical's revenue was $646.21B, beating the average analysts' forecast of $638.82M by 101056.56%. The company's EBITDA was $14.22B, beating the average prediction of $38.16M by 37161.46%. BioMarin Pharmaceutical's net income was $20.38B, beating the average estimation of $38.87M by 52318.99%. The company's SG&A was $275.02B, beating the average forecast of $255.82M by 107407.91%. Lastly, the company's EPS was $0.11, missing the average prediction of $0.197 by -44.21%